Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Sofosbuvir; Velpatasvir

February 2026

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredients: Sofosbuvir; Velpatasvir

Dosage Form: Pellets

Route: Oral

Strengths: 150 mg; 37.5 mg/packet, 200 mg; 50 mg/packet

Recommended Studies: Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 200 mg; 50 mg/packet at the administered dose of 400 mg for sofosbuvir and 100 mg for velpatasvir
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: Exclude subjects with evidence of current or prior hepatitis B virus infection due to the risk of reactivation. Pellets should be swallowed whole. Do not chew pellets. Follow the administration instructions described in the reference listed drug (RLD) labeling.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 200 mg; 50 mg/packet at the administered dose of 400 mg for sofosbuvir and 100 mg for velpatasvir
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: See comments above.

Analytes to measure: Sofosbuvir and velpatasvir in plasma

Bioequivalence based on (90% CI): Sofosbuvir and velpatasvir

Waiver request of in vivo testing of additional strength: Justification based on (i) acceptable bioequivalence studies on the 200 mg; 50 mg/packet strength, (ii) acceptable comparative in vitro dissolution studies between additional strength and the 200 mg; 50 mg/packet strength using 12 units per strength, and (iii) proportional similarity of the formulations between both strengths

Dissolution: Dissolution test(s) should be included for quality control and to support waiver request of in vivo testing of additional strength.

Dissolution test method and sampling times: Provide a dissolution method development report for the test product containing information and data that demonstrate appropriateness of the selected dissolution method[1] and sampling times, such as the discriminating ability to detect changes in critical quality attributes that could potentially impact drug product performance.

For drug products containing high solubility drug substances that meet the rapidly dissolving criteria, demonstration of discriminating ability may not be needed. For additional information, refer to the most recent version of the guidance for industry *Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances*.[a]

Document History: Recommended February 2026

Unique Agency Identifier: PSG_214187

[a] For the most recent version of a guidance, refer to the FDA guidance website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.

[1] Applicant-developed, United States Pharmacopeia drug product monograph or Dissolution Methods database, https://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm.